Biphenyl compound

A compound represented by formula (I):

• 756
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 8 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group;
• R2 and R3 each represents an optionally substituted hydrocarbon group, and rings B and C each represents a further optionally substituted benzene ring, or a salt thereof, provided that 4′-[[(methoxyacetyl)methylamino]methyl]-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2′-methyl-[1,1′-biphenyl]-4-carboxamide is excluded.

A pharmaceutical composition comprising a compound represented by the formula (I):

• 766
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 12 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group;
• R2 represents an optionally substituted hydrocarbon group or an optionally substituted amino group;
• R3 represents an optionally substituted hydrocarbon group;
• and rings B and C each represents a further optionally substituted benzene ring, provided that (1) a compound represented by the formula:
• 767
• wherein each symbol has the same meaning as defined above, and (2) 4′-[[(methoxyacetyl)methylamino]methyl]-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2′-methyl-[1,1′-biphenyl]-4-carboxamide are excluded, or a salt thereof or a prodrug thereof.

A GPR14 antagonist comprising a compound represented by the formula (I):

• 768
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 12 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group;
• R2 represents an optionally substituted hydrocarbon group or an optionally substituted amino group;
• R3 represents an optionally substituted hydrocarbon group;
• and rings B and C each represents a further optionally substituted benzene ring, or a salt thereof or a prodrug thereof.

A vasoconstriction inhibitor comprising a compound represented by the formula (I):

• 769
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 12 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group;
• R2 represents an optionally substituted hydrocarbon group or an optionally substituted amino group;
• R3 represents an optionally substituted hydrocarbon group;
• and rings B and C each represents a further optionally substituted benzene ring, or a salt thereof or a prodrug thereof.

An agent for preventing and/or treating hypertension, arteriosclerosis, cardiac hypertrophy, myocardial infarction or heart failure, comprising a compound represented by the formula (I):

• 770
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 12 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group;
• R2 represents an optionally substituted hydrocarbon group or an optionally substituted amino group;
• R3 represents an optionally substituted hydrocarbon group;
• and rings B and C each represents a further optionally substituted benzene ring, or a salt thereof or a prodrug thereof.

A regulator for a somatostatin receptor function comprising a compound represented by the formula (I):

• 771
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 12 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group, R2 represents an optionally substituted hydrocarbon group or an optionally substituted amino group;
• R3 represents an optionally substituted hydrocarbon group;
• and rings B and C each represents a further optionally substituted benzene ring, or a salt thereof or a prodrug thereof.

A method of antagonizing GPR14, which comprises administering, into a mammal, an effective amount of a compound represented by the formula (I):

• 772
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 12 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group;
• R2 represents an optionally substituted hydrocarbon group or an optionally substituted amino group;
• R3 represents an optionally substituted hydrocarbon group;
• and rings B and C each represents a further optionally substituted benzene ring, or a salt thereof.

A method of regulating a somatostatin receptor function which comprises administering, into a mammal, an effective amount of a compound represented by the formula (I):

• 773
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 12 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group;
• R2 represents an optionally substituted hydrocarbon group or an optionally substituted amino group;
• R3 represents an optionally substituted hydrocarbon group;
• and rings B and C each represents a further optionally substituted benzene ring, or a salt thereof.

Use of a compound represented by the formula (I):

• 774
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 12 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group;
• R2 represents an optionally substituted hydrocarbon group or an optionally substituted amino group;
• R3 represents an optionally substituted hydrocarbon group;
• and rings B and C each represents a further optionally substituted benzene ring, or a salt thereof, for the manufacture of a GPR14 antagonist.

Use of a compound represented by the formula (I):

• 775
• wherein R1 represents hydrogen atom or an optionally substituted hydrocarbon group;
• X represents a spacer whose linear chain moiety is composed of 1 to 12 carbon atoms;
• R1 and X may be bound to each other to form a ring;
• A represents an optionally substituted amino group or an optionally substituted nitrogen-containing heterocyclic group;
• R2 represents an optionally substituted hydrocarbon group or an optionally substituted amino group;
• R3 represents an optionally substituted hydrocarbon group;
• and rings B and C each represents a further optionally substituted benzene ring, or a salt thereof, for the manufacture of a somatostatin receptor regulator.